Investor Relations | Press Releases
MediciNova Initiates a Second Phase I Clinical Trial with MN-029 in Cancer Patients
Novel Vascular Targeting Agent Well Tolerated in Earlier Trial
SAN DIEGO, Calif. - June 17, 2005 -- MediciNova, Inc., a specialty pharmaceutical company that is publicly traded on the Hercules Market of the Osaka Securities Exchange (Code number: 4875), today announced the initiation of a second Phase I study with MN-029 in patients with solid tumors. MN-029 is a vascular targeting agent (VTA) that in preclinical studies demonstrated greater potency with possibly less cardiovascular and central nervous system toxicity than first generation VTAs. In September of 2004, the Company initiated a Phase I clinical trial in patients with solid tumors. That study is nearing completion.
"MN-029 has been well tolerated at each dosing level throughout the current Phase I clinical study, and we are planning in this second study to implement a more aggressive, yet simpler dosing schedule that will be compatible with a wide range of cancer treatment regimens," stated Richard E. Gammans, Ph.D., Chief Development Officer at MediciNova.
MediciNova has exclusive worldwide rights to MN-029, which was acquired from Angiogene Pharmaceuticals of Oxford, U.K., in 2002.
Contact
Shintaro Asako
MediciNova, Inc. (USA)
Phone: (858)373-1500
Email: asako@medicinova.com
More Information
Click for more information on the following items:
